Lung Cancer Trial, Not Yet Recruiting NCT07632703 Sponsor: Feifei Huang Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Not Yet Recruiting

NCT07632703
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with primary lung cancer, confirmed through a tissue or cell sample test
  • People who are receiving combination drug therapy for the first time, with a planned treatment course of at least 4 cycles (the specific drug combination does not matter)
  • People aged 18 years or older
  • People who are able to use a smartphone
  • People whose general physical functioning is rated at a certain level (a score of 2 or lower on a standard medical scale used to measure how much a condition affects daily activity — confirm with trial site)
  • People who are aware of their own diagnosis and the medications they are taking
  • People who agree to take part in the study voluntarily

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have a history of mental illness or who are currently receiving mental health treatment
  • People who have been diagnosed with cancer in another part of the body (other than the lung)
  • People who show signs of cognitive impairment, based on a short memory and thinking test (specifically, making 3 or more errors on the Short Portable Mental Status Questionnaire)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Feifei Huang, Fujian Medical University

Phone: +86 13763869099

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Feifei Huang
Registry
ClinicalTrials.gov
Start date
25 May 2026
Est. completion
30 June 2027

Primary endpoints

Change in symptom burden measured by the Symptom Assessment Scale for Intervals of Combination Therapy in Patients with Lung Cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov